1419221-30-9

Upstream product

• 180516-87-4 4-carboxyphenylboronic acid pinacol ester 
• 944401-77-8 4-fluoropyridin-2-amine 
• 380499-68-3 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid chloride 

Relevant academic research and scientific papers

Irreversible BTK inhibitor with oxazolo [4, 5-b] pyridine structure and application of irreversible BTK inhibitor

The invention discloses a compound capable of irreversibly inhibiting the activity of protein tyrosine kinase (BTK), pharmaceutically available salts of the compound, a synthesis method of the compound and application of the compound in medicines for inhibiting BTK protein. In particular, compounds of Formula A are described. The compound disclosed by the invention has good BTK inhibitory activity, the water solubility is also improved, and the pharmacokinetic parameters of the compound are basically consistent with those of a positive drug ibrutinib on the market, so that the compound can be widely applied to preparation of pharmaceutical preparations for preventing or treating diseases caused by BTK abnormality.

Aminonorbornane derivative and preparation method and application thereof

The invention discloses an aminonorbornane derivative and a preparation method and application thereof and relates to a compound having a structure represented by a formula I which is described in thespecification or a pharmaceutically acceptable salt, a solvate, an active metabolite, a polymorph, an ester, an optical isomer or a prodrug thereof, a pharmaceutical composition comprising the compound as shown in the formula I, and application of the compound and the pharmaceutical composition as highly selective Bruton's tyrosine kinase (BTK) inhibitors of BTK (C481S) mutants for preparation ofdrugs used for prevention or treatment of heteroimmune diseases, autoimmune diseases or cancer.

Bruton's tyrosine kinase inhibitor

The invention relates to a compound with a formula I and a pharmaceutically acceptable salt, a solvent compound, an active metabolite, a polycrystalline compound, an ester, an isomer or a prodrug thereof, a pharmaceutical composition containing the compound in the formula I, and application using the same as a selective Bruton's tyrosine kinase inhibitor to prepare a medicine for preventing or treating heterologous immunity diseases and self immunity diseases or cancers. The formula is shown in the specification.

4 - IMIDAZOPYRIDAZIN- 1 -YL-BENZAMIDES AND 4 - IMIDAZOTRIAZIN- 1 - YL - BENZAMIDES AS BTK- INHIBITORS

The present invention relates to 6-5 membered fused pyridine ring compounds according to formula (I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds according to formula I in the treatment of Brutons Tyrosine Kinase (Btk) mediated disorders.

4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors

The present invention provides 6-5 membered fused pyridine ring compounds according to Formula I or pharmaceutically acceptable salts thereof. or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.